HJLI Hancock Jaffe Laboratories Inc

This Amendment No. 2 is being filed jointly by the Reporting Persons and amends the Schedule 13G initially filed by the Reporting Persons with the Securities and Exchange Commission (the “SEC”) on July 30, 2020, as amended by Amendment No. 1 thereto filed by the Reporting Persons with the SEC on January 29, 2021 (the “Schedule 13G”).

Except as set forth below, all Items of the Schedule 13G remain unchanged. All capitalized terms not otherwise defined herein shall have the meanings ascribed to such terms in the Schedule 13G.

Item 1.

(a) Name of Issuer

enVVeno Medical Corporation (the “Issuer”)

(b) Address of Issuer’s Principal Executive Offices

70 Doppler

Irvine, California 92618

Item 2.

(e) CUSIP Number

29415J106

Item 4. Ownership.

(a) and (b):

As of the close of business of December 31, 2021, each of the Reporting Persons may have been deemed to have beneficial ownership of 431,213 shares of Common Stock, which consisted of (i) 16,956 shares of Common Stock issuable upon exercise of a warrant held by Intracoastal (“Intracoastal Warrant 1”), (ii) 12,500 shares of Common Stock issuable upon exercise of a second warrant held by Intracoastal (“Intracoastal Warrant 2”), (iii) 38,611 shares of Common Stock issuable upon exercise of a third warrant held by Intracoastal (“Intracoastal Warrant 3”), (iv) 123,364 shares of Common Stock issuable upon exercise of a fourth warrant held by Intracoastal (“Intracoastal Warrant 4”), (v) 25,157 shares of Common Stock issuable upon exercise of a fifth warrant held by Intracoastal (“Intracoastal Warrant 5”), (vi) 340 shares of Common Stock issuable upon exercise of a sixth warrant held by Intracoastal (“Intracoastal Warrant 6”) and (vii) 214,285 shares of Common Stock issuable upon exercise of a seventh warrant held by Intracoastal (“Intracoastal Warrant 7”), and all such shares of Common Stock in the aggregate represent beneficial ownership of approximately 4.4% of the Common Stock, based on (1) 9,468,324 shares of Common Stock outstanding on November 9, 2021 as reported by the Issuer, plus (2) 16,956 shares of Common Stock issuable upon exercise of Intracoastal Warrant 1, (3) 12,500 shares of Common Stock issuable upon exercise of Intracoastal Warrant 2, (4) 38,611 shares of Common Stock issuable upon exercise of Intracoastal Warrant 3, (5) 123,364 shares of Common Stock issuable upon exercise of Intracoastal Warrant 4, (6) 25,157 shares of Common Stock issuable upon exercise of Intracoastal Warrant 5, (7) 340 shares of Common Stock issuable upon exercise of Intracoastal Warrant 6 and (8) 214,285 shares of Common Stock issuable upon exercise of Intracoastal Warrant 7.

(c) Number of shares as to which each Reporting Person has:

(i) Sole power to vote or to direct the vote: 0.

(ii) Shared power to vote or to direct the vote: 431,213.

(iii) Sole power to dispose or to direct the disposition of 0.

(iv) Shared power to dispose or to direct the disposition of 431,213.

Item 5. Ownership of Five Percent or Less of a Class

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following þ.

Item 10. Certification

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: February 11, 2022